The therapeutic effects of KY19334 on metabolic diseases phenotypes were acquired by restoration of suppressed Wnt/β‐catenin pathway via blockade of the functions of the aberrantly overexpressed Cxxc5. The gene discussed is CXXC5; the disease is Other metabolic disease.